Brief: Tonix Pharmaceuticals Announces First Patient Dosed In Phase 2 Oasis Study Of TNX-102 SL For Reduction Of Acute Stress Reaction
21/05/2025 12:20
May 21 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 OASIS STUDY OF TNX-102 SL FOR REDUCTION OF ACUTE STRESS REACTION TONIX PHARMACEUTICALS HOLDING CORP - TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2026 Source text: ID:nGNX9gmZXX Further company coverage: TNXP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview